InMed reports INM-901 reduces IL-6 and IL-8 in human Alzheimer’s brain organoid models

Reuters

Mar 23

InMed reports INM-901 reduces IL-6 and IL-8 in human Alzheimer’s brain organoid models

InMed reported new preclinical results for INM-901 in 3D human brain organoid models of Alzheimer’s disease–related neuroinflammation.
The studies evaluated INM-901 in an LPS/IFN-γ–induced neuroinflammation organoid model and in a proprietary Alzheimer’s disease neuroinflammation organoid model.
Data showed a dose-dependent reduction in pro-inflammatory markers including IL-6 and IL-8 across both organoid models.
The company said it plans a pre-IND meeting with the FDA in Q3/2026 and is targeting IND submission and Phase 1 initiation in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202603230730NEWSFILECNPR____20260323_289438_1) on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2621377079"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621377079\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621377079?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621377079","market":"nz","top_or_hot":-1,"title":"InMed reports INM-901 reduces IL-6 and IL-8 in human Alzheimer’s brain organoid models","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InMed reports INM-901 reduces IL-6 and IL-8 in human Alzheimer’s brain organoid models\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          InMed reported new preclinical results for INM-901 in 3D human brain organoid models of Alzheimer’s disease–related neuroinflammation.\n        </li>\n<li>\n          The studies evaluated INM-901 in an LPS/IFN-γ–induced neuroinflammation organoid model and in a proprietary Alzheimer’s disease neuroinflammation organoid model.\n        </li>\n<li>\n          Data showed a dose-dependent reduction in pro-inflammatory markers including IL-6 and IL-8 across both organoid models.\n        </li>\n<li>\n          The company said it plans a pre-IND meeting with the FDA in Q3/2026 and is targeting IND submission and Phase 1 initiation in 2027.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/INM\">InMed Pharmaceuticals Inc</a>. published the original content used to generate this news brief via Newsfile (Ref. ID: 202603230730NEWSFILECNPR____20260323_289438_1) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InMed reports INM-901 reduces IL-6 and IL-8 in human Alzheimer’s brain organoid models</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInMed reports INM-901 reduces IL-6 and IL-8 in human Alzheimer’s brain organoid models\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 19:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InMed reports INM-901 reduces IL-6 and IL-8 in human Alzheimer’s brain organoid models\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          InMed reported new preclinical results for INM-901 in 3D human brain organoid models of Alzheimer’s disease–related neuroinflammation.\n        </li>\n<li>\n          The studies evaluated INM-901 in an LPS/IFN-γ–induced neuroinflammation organoid model and in a proprietary Alzheimer’s disease neuroinflammation organoid model.\n        </li>\n<li>\n          Data showed a dose-dependent reduction in pro-inflammatory markers including IL-6 and IL-8 across both organoid models.\n        </li>\n<li>\n          The company said it plans a pre-IND meeting with the FDA in Q3/2026 and is targeting IND submission and Phase 1 initiation in 2027.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/INM\">InMed Pharmaceuticals Inc</a>. published the original content used to generate this news brief via Newsfile (Ref. ID: 202603230730NEWSFILECNPR____20260323_289438_1) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL74Rx3m:1","article_id":"2621377079","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621377079","pubTimestamp":1774265526,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"InMed reported new preclinical results for INM-901 in 3D human brain organoid models of Alzheimer’s disease–related neuroinflammation.The studies evaluated INM-901 in an LPS/IFN-γ–induced neuroinflammation organoid model and in a proprietary Alzheimer’s disease neuroinflammation organoid model.Data showed a dose-dependent reduction in pro-inflammatory markers including IL-6 and IL-8 across both organoid models.The company said it plans a pre-IND meeting with the FDA in Q3/2026 and is targeting IND submission and Phase 1 initiation in 2027.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","INM":"InMed Pharmaceuticals Inc"},"translate_title":"InMed报道INM-901可降低人类阿尔茨海默病脑类器官模型中的IL-6和IL-8","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INM":0.9},"content_text":"InMed reports INM-901 reduces IL-6 and IL-8 in human Alzheimer’s brain organoid models\n    \n\n\n          InMed reported new preclinical results for INM-901 in 3D human brain organoid models of Alzheimer’s disease–related neuroinflammation.\n        \n\n          The studies evaluated INM-901 in an LPS/IFN-γ–induced neuroinflammation organoid model and in a proprietary Alzheimer’s disease neuroinflammation organoid model.\n        \n\n          Data showed a dose-dependent reduction in pro-inflammatory markers including IL-6 and IL-8 across both organoid models.\n        \n\n          The company said it plans a pre-IND meeting with the FDA in Q3/2026 and is targeting IND submission and Phase 1 initiation in 2027.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202603230730NEWSFILECNPR____20260323_289438_1) on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}